In this meta-analysis, researchers aimed to characterize the relationship between sentinel node biopsy and melanoma survival.

Lymphatic mapping, a recent technique first developed for the management of melanoma, is based on the concept that information about the status of the entire lymphatic drainage from a tumor site could ...

Please provide your email address to receive an email when new articles are posted on . Similar proportions of older women with node-negative and node-positive early breast cancer had Oncotype Dx ...

Please provide your email address to receive an email when new articles are posted on . Sentinel lymph node biopsy (SLNB) is a low-risk procedure that can reduce the need for complete lymph node ...

Lymph node status in stage I hormone receptor-positive/HER2-negative breast cancer was not a good indicator of genetic-risk scores that would qualify older women for ...

Over the last decade, the use of sentinel node biopsy has reduced the number of patients who need a full axillary lymph node dissection for treatment and staging of breast cancer.This represents a ...

A meta-analysis of 13 studies showed that patients who underwent sentinel node biopsy had a significantly reduced risk of death from melanoma. In addition, an analysis of nine studies showed that the ...

A test that combines clinicopathologic factors and a tumor’s gene expression profile (CP-GEP) reliably identified patients with a less than 10% risk for a positive sentinel lymph node biopsy — though ...

Researchers at the UPMC Hillman Cancer Center used UPMC-owned Realyze Intelligence technology to understand the utility of sentinel lymph node biopsy, or SLNB, for early-stage breast cancer patients ...

Epirubicin Increases Long-Term Survival in Adjuvant Chemotherapy of Patients With Poor-Prognosis, Node-Positive, Early Breast Cancer: 10-Year Follow-Up Results of the French Adjuvant Study Group 05 ...

Limited data are available on survival outcomes after sentinel-lymph-node biopsy alone as compared with lymphadenectomy in cervical cancer. In this multicenter, randomized, noninferiority trial, we ...